Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells
about
Involvement of autophagy in ovarian cancer: a working hypothesisLysophosphatidic acid production and action: critical new players in breast cancer initiation and progressionInteraction between circulating cancer cells and platelets: clinical implicationCellular deficiency in the RGS10 protein facilitates chemoresistant ovarian cancerRole of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapyLysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expressionBisphenol-A: epigenetic reprogramming and effects on reproduction and behaviorExocrine pancreatic carcinogenesis and autotaxin expressionHigher LPA2 and LPA6 mRNA Levels in Hepatocellular Carcinoma Are Associated with Poorer Differentiation, Microvascular Invasion and Earlier Recurrence with Higher Serum Autotaxin LevelsLoss of lysophosphatidic acid receptor-3 suppresses cell migration activity of human sarcoma cells.Negative regulation of cell motile and invasive activities by lysophosphatidic acid receptor-3 in colon cancer HCT116 cells.Decreased peritoneal ovarian cancer growth in mice lacking expression of lipid phosphate phosphohydrolase 1.Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis.Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity.Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers.Lysophosphatidic acid enhanced the angiogenic capability of human chondrocytes by regulating Gi/NF-kB-dependent angiogenic factor expressionLysophosphatidic acid (LPA) receptors: signaling properties and disease relevance.Endosomal H2O2 production leads to localized cysteine sulfenic acid formation on proteins during lysophosphatidic acid-mediated cell signalingRole of LPAR3, PKC and EGFR in LPA-induced cell migration in oral squamous carcinoma cells.LPA receptor signaling: pharmacology, physiology, and pathophysiology.Hax-1 is required for Rac1-Cortactin interaction and ovarian carcinoma cell migration.Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid.Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer.Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature.Lysophospholipid receptor nomenclature review: IUPHAR Review 8.Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases.ATX-LPA receptor axis in inflammation and cancer.Microarray analysis reveals distinct gene expression profiles among different tumor histology, stage and disease outcomes in endometrial adenocarcinoma.Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells.Aiming drug discovery at lysophosphatidic acid targets.Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancerIntegrity of SOS1/EPS8/ABI1 tri-complex determines ovarian cancer metastasis.Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer.Lysophosphatidic acid in vascular development and diseaseActivation of AMP-activated protein kinase is essential for lysophosphatidic acid-induced cell migration in ovarian cancer cells.Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment.Lysophosphatidic Acid Stimulates the Proliferation of Ovarian Cancer Cells via the gep Proto-Oncogene Gα(12).Effects of lysophospholipids on tumor microenvironmentLysophosphatidic Acid Mediates Activating Transcription Factor 3 Expression Which Is a Target for Post-Transcriptional Silencing by miR-30c-2-3p.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.
P2860
Q21198790-60EDE568-4CD9-41F7-8056-9F00771590FBQ24616764-0FEEA0A2-C6F1-470D-905E-4173113E3CD8Q26778920-796C7C6D-2511-4FF5-AC51-B190980C9D18Q26796258-EA03F6F1-86EB-4907-B902-11F2875B3D24Q27015257-630D488C-3F95-4384-8B2E-B54172F75993Q28299091-9166F8BC-C033-4335-ADCD-010B825B71C3Q28391200-CD8DEA8C-1CA2-4069-B422-70540A8BC8B6Q28482954-BAAEFD16-C5EC-4C8A-865E-96B9377E1E6FQ29048613-B31B2A53-E5E9-4601-AB7A-19EEDDCC1C49Q30009974-00EAE8BC-2969-4770-9320-0864DEE2D581Q30010057-B19B3F31-7CB1-477C-9AD8-B2850C82DDDEQ30300375-81346B2E-336E-4E5B-B50E-AE75CD649937Q30489645-6BE77F15-4C0F-4AD1-8103-DEC69F4CAB9EQ30573574-4A65CF6F-1439-4BA0-AA45-FC4B1118C1D2Q33610285-DDF6EF46-049A-4D01-8547-90F8CEC6CD31Q33689905-20466943-8BAC-452B-A57D-681BCD81EACAQ33753311-428701CE-F0B4-4E52-ABE3-AB05B478A149Q33781318-01FBBCE5-BCC6-4A45-869C-598D8364A849Q33786333-805C2EE8-9C0E-44B6-AC82-7C33DBEBA95FQ33825153-11700B23-0993-4AD5-BC73-5A35C03AB78EQ33880112-B764ACAB-AC4A-43BC-8C38-EC78B6359E7BQ33955207-439463DD-6E5B-4E33-8D1B-F7B105B45BE2Q33972424-8B81C17B-1321-4E10-9EFF-16E2389BF5D7Q33974891-A62ABCE4-37CE-472B-8142-F4B09AF856FDQ34025135-7086D791-575B-4212-900B-AEBEDAAED1EBQ34148745-174F83C9-E386-4C93-95CF-86C0BE0F6C19Q34199719-3403166E-5DB5-4561-94C3-A01A80120299Q34287768-3D64BBA1-37A6-458B-9DF9-0C6FECB4ABDDQ34335443-FB4B3A4F-C38D-484D-BFE5-C068CA6F6E21Q34339759-DBF71C54-A250-4A50-9B15-8577226CBBD0Q34517736-349C98DF-8043-488D-8CC8-FCC8B1773804Q34685562-6F3B1916-5304-4286-AA43-A88F2FA5EA49Q34785252-C081016D-F69F-4556-BB61-712A2536CA60Q35018207-FDA18689-F8CC-4976-B9C2-8520702A9109Q35085076-A8559986-E0F1-497C-9423-67057051E290Q35098085-97D3CE80-B3A1-4BCF-A525-DD14274B659DQ35180349-324FB430-4228-4B76-BEB9-6560F4400F8EQ35603140-03E130D0-E9C4-4BB3-8E38-8C44665AC577Q35791587-22D87950-C420-4991-A3C0-5CC9DE8CCBF5Q35837949-FCECDCCD-E4C8-4643-913E-1F97F7E64225
P2860
Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Lysophosphatidic acid receptor ...... veness of ovarian cancer cells
@en
Lysophosphatidic acid receptor ...... eness of ovarian cancer cells.
@nl
type
label
Lysophosphatidic acid receptor ...... veness of ovarian cancer cells
@en
Lysophosphatidic acid receptor ...... eness of ovarian cancer cells.
@nl
prefLabel
Lysophosphatidic acid receptor ...... veness of ovarian cancer cells
@en
Lysophosphatidic acid receptor ...... eness of ovarian cancer cells.
@nl
P2093
P2860
P356
P1476
Lysophosphatidic acid receptor ...... veness of ovarian cancer cells
@en
P2093
Clifton Stephens
Gordon B Mills
Hassan S Hall
Jinsong Liu
Mandi M Murph
Shuangxing Yu
Shuying Liu
Xianjun Fang
P2860
P304
P356
10.1093/JNCI/DJN378
P407
P577
2008-11-11T00:00:00Z